PA
PTGX icon

Profund Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Profund Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.41M Sell
22,867
-2,707
-11% -$240K 0.09% 161
2025
Q4 		$2.23M Buy
25,574
+7,417
+41% +$607K 0.07% 196
2025
Q3 		$1.21M Sell
18,157
-917
-5% -$52.1K 0.04% 287
2025
Q2 		$1.05M Buy
19,074
+7,515
+65% +$361K 0.04% 289
2025
Q1 		$559K Sell
11,559
-9,090
-44% -$381K 0.02% 435
2024
Q4 		$797K Buy
20,649
+566
+3% +$24.7K 0.03% 343
2024
Q3 		$904K Buy
20,083
+5,554
+38% +$224K 0.03% 346
2024
Q2 		$503K Sell
14,529
-22,946
-61% -$672K 0.02% 492
2024
Q1 		$1.08M Buy
37,475
+9,585
+34% +$261K 0.04% 339
2023
Q4 		$640K Sell
27,890
-30,826
-53% -$539K 0.03% 441
2023
Q3 		$979K Buy
58,716
+6,933
+13% +$135K 0.05% 288
2023
Q2 		$1.43M Buy
51,783
+22,983
+80% +$575K 0.08% 224
2023
Q1 		$662K Buy
+28,800
New +$484K 0.04% 419

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Profund Advisors's PTGX Position: Q1 2026 in Review

Profund Advisors reduced its Protagonist Therapeutics (PTGX) stake by 11% in Q1 2026, selling an estimated $240K and leaving 22,867 shares worth $2.41M. The position accounts for 0.09% of the portfolio, ranked #161.

Profund Advisors first reported a position in PTGX in Q1 2023 and has held it in 13 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Profund Advisors held 22,867 shares of Protagonist Therapeutics worth $2.41M as of Q1 2026.
  • Profund Advisors sold 2,707 Protagonist Therapeutics shares in Q1 2026, an estimated $240K.
  • Protagonist Therapeutics made up 0.09% of Profund Advisors's portfolio in Q1 2026, its #161 holding.
  • Profund Advisors first reported a position in Protagonist Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.